4 days ago · OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016. ... 226950), a leading developer of RNAi therapeutics, today ...

4 days ago · Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

4 days ago · SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company (“Lilly”).This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other ...

1 day ago · Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. MASH, also known as nonalcoholic steatohepatitis, occurs when too much fat builds up in the liver.

4 days ago · SEONGNAM, South Korea, February 10, 2025--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016.

3 days ago · OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX’s OLX75016, a Phase I candidate primarily targeting metabolic-associated steatohepatitis and other cardiometabolic indications.OLX75016 derives from a genome-wide association study (GWAS). South Korea-based OliX will receive an initial payment from Lilly to com

Olix will use the upfront payment to complete a phase 1 clinical trial for its candidate OLX702A in Australia while Eli Lilly will work on further research, development and commercialization.

4 days ago · OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly . This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily ...

3 days ago · Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease with an RNA-based asset. Known as OLX75016, the candidate is an antisense RNAi oligonucleotide developed using OliX’s therapeutic RNAi platform.

4 days ago · Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016, a ...